Pomalyst (pomalidomide)
An approved treatment for Multiple Myeloma.
Drug facts
The same compound appears under different names depending on the context. Here is how to identify Pomalidomide wherever you encounter it, plus the key facts at a glance.
- Generic name
- Pomalidomide
- Brand name
- Pomalyst
- Development code
- CC-4047
- Drug class
- Immunomodulatory drug (thalidomide analogue)
- Manufacturer
- Bristol Myers Squibb (Celgene Corporation); generic pomalidomide is made by several companies
- How it's taken
- Capsule by mouth once daily on days 1 to 21 of each 28-day cycle, with dexamethasone
Pomalyst (pomalidomide) is a daily capsule related to thalidomide, taken with dexamethasone by adults whose myeloma progressed after lenalidomide and a proteasome inhibitor[1].
- The label limits Pomalyst to people who have had at least 2 prior therapies and whose myeloma progressed during or within 60 days of the last one[1].
- The FDA granted accelerated approval on February 8, 2013, and on April 23, 2015 confirmed the benefit and revised the indication to the dexamethasone combination[3][4].
- In the MM-003 trial of 455 people, median overall survival was 12.4 months with Pomalyst and low-dose dexamethasone versus 8.0 months with high-dose dexamethasone[1][10].
- Pomalyst carries a boxed warning for birth defects and blood clots and is available only through the PS-Pomalidomide REMS safety program[1][6].
- Generic pomalidomide capsules from several companies are FDA approved and rated as substitutable for Pomalyst[7].
We'll email you when Pomalyst's FDA label changes, when the FDA acts on it, and when new trials for Multiple Myeloma open. Unsubscribe anytime.
- Trial Alerts, when a new trial opens or a trial changes
- Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site
Where Pomalidomide fits
The Pomalyst label covers adults with myeloma who have received at least 2 prior therapies, including lenalidomide and a proteasome inhibitor, and whose disease progressed during or within 60 days of the last therapy[1]. It is given with dexamethasone[1]. Pomalidomide is also a named partner in other medicines' myeloma labels, including Empliciti (elotuzumab) and Sarclisa Escena (isatuximab), each combined with pomalidomide and dexamethasone[13][14]. Pomalyst is also approved for Kaposi sarcoma[1].
How Pomalidomide works
Pomalidomide is a close chemical relative of thalidomide and lenalidomide, and its label describes it as having immune-boosting, blood-vessel-blocking and anticancer properties[1]. Inside cells, pomalidomide attaches to cereblon, a protein that helps tag other proteins for disposal[1].
With pomalidomide attached, cereblon marks the proteins Ikaros and Aiolos for breakdown, which harms myeloma cells directly and changes how immune cells behave[1]. The label lists these effects from laboratory studies:
- Myeloma cells stop multiplying and die, including cell lines that had become resistant to lenalidomide[1]
- Pomalidomide and dexamethasone together killed myeloma cells better than either alone, in both lenalidomide-sensitive and lenalidomide-resistant cells[1]
- T cell and natural killer (NK) cell immunity was strengthened, and inflammatory signals such as TNF-alpha and IL-6 were reduced[1]
These laboratory findings help explain why Pomalyst is used with dexamethasone after lenalidomide has stopped working[1].
Side effects and safety
- Embryo-fetal toxicity. Contraindicated in pregnancy; pregnancy tests and 2 forms of birth control for women who can become pregnant, condoms for men, from 4 weeks before until 4 weeks after treatment.
- Venous and arterial thromboembolism. Blood clots in 8.0% versus 3.3% with high-dose dexamethasone in MM-003; clot-prevention medicine is recommended.
- Increased mortality with pembrolizumab. Adding pembrolizumab to a thalidomide analogue and dexamethasone raised deaths in 2 trials and is not recommended outside trials.
- Hematologic toxicity. Severe neutropenia in 46% and febrile neutropenia in 8%; blood counts weekly for 8 weeks, then monthly.
- Hepatotoxicity. Liver failure, including deaths, has occurred; liver tests are checked monthly.
- Severe cutaneous reactions. Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS can be fatal; Pomalyst is stopped permanently for these.
- Dizziness and confusional state. Dizziness in 14% and confusion in 7%; the label advises avoiding situations where these could be dangerous.
- Neuropathy. Nerve damage in 18%, with about 12% peripheral neuropathy and no grade 4 cases.
- Second primary malignancies. Acute myeloid leukemia has been reported with investigational use outside myeloma.
- Tumor lysis syndrome. People with a high tumor burden are monitored closely.
- Hypersensitivity. Angioedema and anaphylaxis have been reported; Pomalyst is stopped permanently if they occur.
- Complete blood counts weekly for the first 8 weeks, then monthly
- Neutrophils at least 500 per mcL and platelets at least 50,000 per mcL before each new cycle
- Liver tests monthly
- Pregnancy tests for women who can become pregnant, as the REMS requires
- Signs of blood clots
- Dizziness, confusion and numbness or tingling
- Skin rashes
Pomalyst carries a boxed warning, the FDA's strongest, for 2 risks: harm to an unborn baby, and blood clots in veins and arteries[1].
Birth defects: pomalidomide is related to thalidomide, a known cause of severe birth defects, and it caused birth defects in rats and rabbits, so Pomalyst must never be taken during pregnancy[1]. Women who can become pregnant need 2 negative pregnancy tests before starting and must use 2 forms of birth control (or not have heterosexual sex) from 4 weeks before until 4 weeks after treatment[1].
Men must use a latex or synthetic condom with partners who could become pregnant during treatment and for 4 weeks after, even after a vasectomy, and must not donate sperm[1].
Blood clots: in MM-003, where clot-prevention medicine was required, blood clots occurred in 8.0% of people on Pomalyst with low-dose dexamethasone versus 3.3% on high-dose dexamethasone[1]. Vein clots occurred in 4.7% versus 1.3%, and artery clots such as heart attack and stroke in 3.0% versus 1.3%[1].
Other warnings on the label:
- Low neutrophils, the most common severe side effect: any grade in 51% and severe (grade 3 or 4) in 46%, with fever and low neutrophils in 8%[1]
- Liver failure, including deaths, and raised liver enzymes and bilirubin[1]
- Severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, which can be fatal[1]
- Dizziness in 14% and confusion in 7%[1]
- Nerve damage (neuropathy) in 18%, mostly mild, with severe neuropathy in 2% in MM-003[1]
- Acute myeloid leukemia reported in people taking pomalidomide in studies outside myeloma[1]
- Tumor lysis syndrome and allergic reactions including angioedema and anaphylaxis[1]
- Higher death rates in trials that added pembrolizumab to a thalidomide analogue and dexamethasone, a combination the label does not recommend outside trials[1]
In the myeloma trials, the most common side effects (30% or more) were tiredness and weakness, low neutrophils, anemia, constipation, nausea, diarrhea, shortness of breath, upper respiratory infections, back pain and fever[1]. In MM-003, 67% of people on Pomalyst had a dose paused, 27% had a dose reduced and 8% stopped Pomalyst because of side effects[1].
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Pomalidomide
Pomalyst is a capsule swallowed whole with water once a day, with or without food[1]. The label says not to break, chew or open the capsules[1].
Myeloma dosing on the current label:
- A 4mg dose once daily on days 1 to 21 of each 28-day cycle, given with dexamethasone, until the myeloma progresses[1]
- In MM-003, dexamethasone was 40mg on days 1, 8, 15 and 22, or 20mg for people over 75[1]
- A new cycle starts only when neutrophils are at least 500 per mcL and platelets at least 50,000 per mcL, and doses drop by 1mg at a time for low counts[1]
The label lowers the dose to 3mg for people on hemodialysis (taken after dialysis on dialysis days) and for mild or moderate liver impairment, and to 2mg for severe liver impairment[1]. Strong CYP1A2 blockers such as ciprofloxacin and fluvoxamine raise pomalidomide levels, so the label says to avoid them or cut the dose to 2mg[1].
Pomalyst is available only through the PS-Pomalidomide REMS, a restricted program the FDA requires because of the risk of birth defects[1][6]. Prescribers and pharmacies must be certified, and each patient signs a Patient-Physician Agreement Form and completes a survey[1][6]. Each prescription covers no more than 28 days, with no refills or phone orders, and the pharmacy fills it only when 7 days or less remain on the last supply[6].
Patients may not donate blood during treatment or for 4 weeks after, and unused capsules go back to the REMS, the prescriber or the dispensing pharmacy[1][6]. The label lists the program at www.PS-PomalidomideREMS.com and 1-888-423-5436[1].
Availability and cost
Generic versions may be available at a lower cost. Ask your pharmacist.
Help paying for Pomalyst
With private insurance, the drugmaker's copay card can lower what you pay for Pomalyst. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. Of the 5 charity funds for Multiple Myeloma, 1 was open on October 26, 2026. Pick your insurance below to see which offers fit you.
- Copay help
The BMS Access Support Co-Pay Assistance Program helps commercially insured patients prescribed Pomalyst with deductibles, co-pays or co-insurance. Eligible patients may pay as little as $0 per one-month supply, subject to a maximum benefit. Not available to patients with Medicare, Medicaid, MediGap, CHAMPVA, TRICARE, VA or DoD coverage, or to cash-paying patients.
For: private insurance · source - Other support
BMS Access Support may provide information about, or make a referral to, independent charitable foundations that may help with costs. These foundations are independent of Bristol Myers Squibb and set their own eligibility rules.
For: Medicare, Medicaid, TRICARE, no insurance · source - Insurance and case manager help
BMS Access Support offers coverage and access assistance, help finding local support resources and language translation help. Live support at 1-800-861-0048, 8 AM to 8 PM ET, Monday through Friday.
The official page does not say who qualifies. Ask the program. · source
Good to know: The co-pay terms say monthly, annual or per-claim maximum benefits may apply and can vary with a patient's plan, including co-pay maximizer programs; no dollar cap is published. The Pomalyst co-pay offer is not valid for Massachusetts residents, or for California residents unless they have completed any step therapy or prior authorization their plan requires. Generic pomalidomide is sold by other companies that are not part of this program, so ask your cancer center or specialty pharmacy which version your plan covers.
Charity funds for Multiple Myeloma
- From a charity · HealthWell FoundationMultiple Myeloma (Medicare Access) fundOpen
Pays for: Copays, premiums or other treatment costs. Medicare patients only.
Clinical trial results
MM-003 (NCT01311687), also called NIMBUS, was the phase 3 trial behind Pomalyst's full approval[8][4]. It randomized 455 adults with relapsed and refractory myeloma after at least 2 prior regimens, including lenalidomide and bortezomib, to Pomalyst with low-dose dexamethasone or to high-dose dexamethasone alone[1][10]. Most participants had stopped responding to earlier treatment: 94% were refractory to lenalidomide and 74% to both lenalidomide and bortezomib[1].
MM-003 results from the label:
The earlier phase 2 trial MM-002 (NCT00833833) randomized 221 people whose myeloma had stopped responding to their last therapy and who had received lenalidomide and bortezomib[9][1][11]. Responses occurred in 29.2% on Pomalyst with low-dose dexamethasone versus 7.4% on Pomalyst alone, with a median response length of 7.4 months for the combination[1]. This trial supported the 2013 accelerated approval[3].
Development history
Pomalidomide was developed by Celgene under the code CC-4047, and Drugs@FDA now lists Bristol Myers Squibb, which completed its purchase of Celgene on November 20, 2019, as the application holder[9][2][15].
Myeloma milestones from FDA records:
- February 8, 2013: accelerated approval for myeloma after at least 2 prior therapies including lenalidomide and bortezomib, with progression during or within 60 days of the last one, together with a REMS for birth defect risk[3]
- April 23, 2015: the indication was revised to Pomalyst with dexamethasone after lenalidomide and a proteasome inhibitor, based on MM-003, which fulfilled the accelerated approval requirements[4]
- February 26, 2025: the Pomalyst REMS became the PS-Pomalidomide REMS, a shared program covering Pomalyst and generic pomalidomide[6][5]
- April 27, 2026: the most recent REMS update, which aligned it with the Thalomid and lenalidomide programs[6][5]
Pomalyst is also approved for Kaposi sarcoma in adults with AIDS after antiretroviral therapy has failed and in adults who are HIV-negative, an accelerated approval that Drugs@FDA dates to May 14, 2020[1][2]. That use is outside this page's myeloma focus.
Drugs@FDA lists 11 generic pomalidomide applications, the first approved on October 30, 2020[7]. Another 5 were approved between August 31 and September 2, 2026[7]. As of November 4, 2026, 10 carry a prescription marketing status with an AB rating, meaning substitutable for Pomalyst, and 1 is listed as discontinued[7]. FDA records give approval dates but not the date each generic reached pharmacies. The prescribing information on DailyMed was last revised in February 2025[1].
Explore Multiple Myeloma trials
Other Multiple Myeloma treatments
Pomalyst belongs to the immunomodulatory drug class with thalidomide and Revlimid (lenalidomide), all chemical relatives that each have a REMS for birth defect risk[6][12]. Because its label requires prior lenalidomide and a proteasome inhibitor, Pomalyst is typically used later in treatment than Revlimid[1][12]. Pomalidomide is combined with antibody drugs such as Empliciti and Sarclisa Escena in their own approved regimens[13][14]. In MM-003, its pivotal head-to-head trial, Pomalyst with low-dose dexamethasone was compared directly with high-dose dexamethasone alone[1].
Common questions about Pomalidomide
▸What is Pomalidomide (Pomalyst)?
Pomalyst (pomalidomide) is a daily capsule related to thalidomide, taken with dexamethasone by adults whose myeloma progressed after lenalidomide and a proteasome inhibitor[1]. The label limits Pomalyst to people who have had at least 2 prior therapies and whose myeloma progressed during or within 60 days of the last one[1]. The FDA granted accelerated approval on February 8, 2013, and on April 23, 2015 confirmed the benefit and revised the indication to the dexamethasone combination[3][4]. In the MM-003 trial of 455 people, median overall survival was 12.4 months with Pomalyst and low-dose dexamethasone versus 8.0 months with high-dose dexamethasone[1][10]. Pomalyst carries a boxed warning for birth defects and blood clots and is available only through the PS-Pomalidomide REMS safety program[1][6]. Generic pomalidomide capsules from several companies are FDA approved and rated as substitutable for Pomalyst[7].
▸How does Pomalidomide work?
Pomalidomide is a close chemical relative of thalidomide and lenalidomide, and its label describes it as having immune-boosting, blood-vessel-blocking and anticancer properties[1]. Inside cells, pomalidomide attaches to cereblon, a protein that helps tag other proteins for disposal[1].
With pomalidomide attached, cereblon marks the proteins Ikaros and Aiolos for breakdown, which harms myeloma cells directly and changes how immune cells behave[1]. The label lists these effects from laboratory studies:
- Myeloma cells stop multiplying and die, including cell lines that had become resistant to lenalidomide[1]
- Pomalidomide and dexamethasone together killed myeloma cells better than either alone, in both lenalidomide-sensitive and lenalidomide-resistant cells[1]
- T cell and natural killer (NK) cell immunity was strengthened, and inflammatory signals such as TNF-alpha and IL-6 were reduced[1]
These laboratory findings help explain why Pomalyst is used with dexamethasone after lenalidomide has stopped working[1].
▸What are the side effects of Pomalidomide?
Pomalyst carries a boxed warning, the FDA's strongest, for 2 risks: harm to an unborn baby, and blood clots in veins and arteries[1].
Birth defects: pomalidomide is related to thalidomide, a known cause of severe birth defects, and it caused birth defects in rats and rabbits, so Pomalyst must never be taken during pregnancy[1]. Women who can become pregnant need 2 negative pregnancy tests before starting and must use 2 forms of birth control (or not have heterosexual sex) from 4 weeks before until 4 weeks after treatment[1]. Men must use a latex or synthetic condom with partners who could become pregnant during treatment and for 4 weeks after, even after a vasectomy, and must not donate sperm[1].
Blood clots: in MM-003, where clot-prevention medicine was required, blood clots occurred in 8.0% of people on Pomalyst with low-dose dexamethasone versus 3.3% on high-dose dexamethasone[1]. Vein clots occurred in 4.7% versus 1.3%, and artery clots such as heart attack and stroke in 3.0% versus 1.3%[1].
Other warnings on the label: Low neutrophils, the most common severe side effect: any grade in 51% and severe (grade 3 or 4) in 46%, with fever and low neutrophils in 8%[1] Liver failure, including deaths, and raised liver enzymes and bilirubin[1] Severe skin reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS, which can be fatal[1] Dizziness in 14% and confusion in 7%[1] Nerve damage (neuropathy) in 18%, mostly mild, with severe neuropathy in 2% in MM-003[1] Acute myeloid leukemia reported in people taking pomalidomide in studies outside myeloma[1] Tumor lysis syndrome and allergic reactions including angioedema and anaphylaxis[1] Higher death rates in trials that added pembrolizumab to a thalidomide analogue and dexamethasone, a combination the label does not recommend outside trials[1]
In the myeloma trials, the most common side effects (30% or more) were tiredness and weakness, low neutrophils, anemia, constipation, nausea, diarrhea, shortness of breath, upper respiratory infections, back pain and fever[1]. In MM-003, 67% of people on Pomalyst had a dose paused, 27% had a dose reduced and 8% stopped Pomalyst because of side effects[1].
▸How is Pomalidomide taken?
Pomalyst is a capsule swallowed whole with water once a day, with or without food[1]. The label says not to break, chew or open the capsules[1].
Myeloma dosing on the current label:
- A 4mg dose once daily on days 1 to 21 of each 28-day cycle, given with dexamethasone, until the myeloma progresses[1]
- In MM-003, dexamethasone was 40mg on days 1, 8, 15 and 22, or 20mg for people over 75[1]
- A new cycle starts only when neutrophils are at least 500 per mcL and platelets at least 50,000 per mcL, and doses drop by 1mg at a time for low counts[1]
The label lowers the dose to 3mg for people on hemodialysis (taken after dialysis on dialysis days) and for mild or moderate liver impairment, and to 2mg for severe liver impairment[1]. Strong CYP1A2 blockers such as ciprofloxacin and fluvoxamine raise pomalidomide levels, so the label says to avoid them or cut the dose to 2mg[1].
Pomalyst is available only through the PS-Pomalidomide REMS, a restricted program the FDA requires because of the risk of birth defects[1][6]. Prescribers and pharmacies must be certified, and each patient signs a Patient-Physician Agreement Form and completes a survey[1][6]. Each prescription covers no more than 28 days, with no refills or phone orders, and the pharmacy fills it only when 7 days or less remain on the last supply[6]. Patients may not donate blood during treatment or for 4 weeks after, and unused capsules go back to the REMS, the prescriber or the dispensing pharmacy[1][6]. The label lists the program at www.PS-PomalidomideREMS.com and 1-888-423-5436[1].
▸Is Pomalidomide FDA approved?
Yes, Pomalidomide (Pomalyst) is FDA approved (2013) for the treatment of Multiple Myeloma.
▸When is Pomalyst used for multiple myeloma?
The Pomalyst label covers adults whose myeloma progressed after at least 2 prior therapies, including lenalidomide and a proteasome inhibitor[1].
Timing: The myeloma must have progressed during the last therapy or within 60 days of finishing it[1].
Partner drug: Pomalyst is taken with dexamethasone, a steroid[1].
Other regimens: Empliciti and Sarclisa Escena labels also pair those antibodies with pomalidomide and dexamethasone[13][14].
Source: Pomalyst prescribing information (DailyMed)
▸Is there a generic for Pomalyst?
Yes, generic pomalidomide capsules are FDA approved and rated AB, meaning a pharmacy can substitute them for Pomalyst[7].
First approvals: The first generic pomalidomide approvals are dated October 30, 2020[7].
How many: Drugs@FDA lists 11 generic applications, 10 with a prescription marketing status and 1 discontinued[7].
Same safety program: Generic pomalidomide is dispensed through the same PS-Pomalidomide REMS as Pomalyst[6].
Source: Drugs@FDA (openFDA) records for pomalidomide; FDA REMS database, PS-Pomalidomide REMS
▸What is the PS-Pomalidomide REMS?
The PS-Pomalidomide REMS is the FDA-required safety program that controls who can prescribe, dispense and receive pomalidomide, because it can cause severe birth defects[1][6].
Name change: It replaced the Pomalyst REMS on February 26, 2025, when generic makers joined a shared program[6].
Patients: Each patient signs a Patient-Physician Agreement Form and completes surveys, and women who can become pregnant have regular pregnancy tests[6].
Supply limits: Each prescription covers no more than 28 days, with no refills or phone orders[6].
Contact: The label lists www.PS-PomalidomideREMS.com and 1-888-423-5436[1].
Source: Pomalyst prescribing information (DailyMed); FDA REMS database, PS-Pomalidomide REMS
▸How is Pomalyst taken?
Pomalyst is a 4mg capsule taken by mouth once a day on days 1 to 21 of each 28-day cycle, with dexamethasone[1].
Food: Pomalyst can be taken with or without food, swallowed whole with water[1].
Lower doses: The label uses 3mg for people on hemodialysis or with mild to moderate liver impairment, and 2mg for severe liver impairment[1].
Interactions: Strong CYP1A2 blockers such as ciprofloxacin and fluvoxamine can raise pomalidomide levels[1].
Source: Pomalyst prescribing information (DailyMed)
▸What are the most common side effects of Pomalyst?
The most common side effects in the myeloma trials were tiredness and weakness, low neutrophils, anemia, constipation, nausea, diarrhea, shortness of breath, upper respiratory infections, back pain and fever[1].
Blood counts: Severe neutropenia occurred in 46%, so blood counts are checked weekly for the first 8 weeks[1].
Blood clots: Clots occurred in 8.0% in MM-003, and the label recommends clot-prevention medicine[1].
Other: Dizziness (14%), confusion (7%) and nerve damage (18%) were also reported[1].
Source: Pomalyst prescribing information (DailyMed)
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. National Library of Medicine, DailyMed (Celgene Corporation, a Bristol-Myers Squibb company) · 2025-02. POMALYST (pomalidomide) capsules, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66
- U.S. Food and Drug Administration · 2026-11. Drugs@FDA: POMALYST, NDA 204026, approval history. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204026
- U.S. Food and Drug Administration · 2013-02-08. NDA 204026 accelerated approval letter: Pomalyst (pomalidomide) capsules. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204026Orig1s000ltr.pdf
- U.S. Food and Drug Administration · 2015-04-23. NDA 204026/S-005/S-006/S-008 supplement approval: revised indication with dexamethasone and fulfillment of Subpart H requirements. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2015/0204026Orig1s005,s006,s008ltr.pdf
- U.S. Food and Drug Administration · 2026-04-27. NDA 204026/S-035 supplement approval: modifications to the PS-Pomalidomide shared system REMS. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/204026Orig1s035ltr.pdf
- U.S. Food and Drug Administration · 2026-04-27. Approved Risk Evaluation and Mitigation Strategies: PS-Pomalidomide Shared System REMS (last update April 27, 2026). https://www.accessdata.fda.gov/scripts/cder/rems/index.cfm?event=RemsDetails.page&REMS=435
- U.S. Food and Drug Administration (openFDA) · 2026-11-04. Drugs@FDA records for all pomalidomide applications, with approval dates, marketing status and therapeutic equivalence codes. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:POMALIDOMIDE&limit=100
- ClinicalTrials.gov · 2026-11. A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma (NIMBUS). https://clinicaltrials.gov/study/NCT01311687
- ClinicalTrials.gov · 2026-11. MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma. https://clinicaltrials.gov/study/NCT00833833
- The Lancet Oncology · 2013-10. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. https://doi.org/10.1016/S1470-2045(13)70380-2
- Blood · 2014-03-20. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. https://doi.org/10.1182/blood-2013-11-538835
- U.S. National Library of Medicine, DailyMed (Celgene Corporation, a Bristol-Myers Squibb company) · 2023-03. REVLIMID (lenalidomide) capsules, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fa97bf5-28a2-48f1-8955-f56012d296be
- U.S. National Library of Medicine, DailyMed (Bristol-Myers Squibb Company). EMPLICITI (elotuzumab) for injection, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80686b7e-f6f4-4154-b5c0-c846425e2d91
- U.S. National Library of Medicine, DailyMed (Sanofi-Aventis U.S. LLC). SARCLISA ESCENA (isatuximab-irfc) injection, full prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07730e8c-1340-4d30-8d71-e20f850db8da
- Bristol-Myers Squibb (via BioSpace) · 2019-11-20. Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company. https://www.biospace.com/article/releases/bristol-myers-squibb-completes-acquisition-of-celgene-creating-a-leading-biopharma-company
- Bristol Myers Squibb · 2026-11. BMS Access Support: Co-Pay and Financial Support Options (Pomalyst co-pay program). https://www.bmsaccesssupport.com/patient/co-pay-financial-support